Canopy Growth Stock News

This article was originally published on TipRanks.com Canopy Growth (WEED) announced Wednesday that it has signed a deal to sell pharmaceutical subsidiary C³ Cannabinoid Compound Company to Dermapharm Holding SE, a European pharmaceutical company based in The post Canopy Growth to Sell C³ Cannabinoid Compound Company appeared first on Smarter Analyst .

The Canadian cannabis company is selling a Germany-based subsidiary.

Canopy Growth Corp. said Wednesday it agreed to sell its Cannabinoid Compound Company GmbH (C3) to Dermapharm Holding SE for up to 122.6 million euros ($138 million). Canopy Growth said the transaction will reduce its short-term capital investment requirements by more than $38.9 million. Shares of Canopy Growth rose 1% in pre-market trades. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Canopy Growth Corporation (Canopy Growth or the Company) (TSX: WEED) (NASDAQ: CGC) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (C3), to Dermapharm Holding SE (Dermapharm) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany. The C³ business develops and manufactures pharmaceutical products and is comprised [] The post Canopy Growth Divests Pharmaceutical C3 Cannabinoid Compound Company appeared first on Technical420 .

Canopy Growth Corp (TSE:WEED) shares hit a new 52-week low during trading on Monday . The company traded as low as C$11.90 and last traded at C$12.09, with a volume of 366383 shares changing hands. The stock had previously closed at C$12.18. WEED has been the topic of a number of research reports. CIBC lowered []

Canopy Growth Corporation (TSX:WEED) (NASDAQ:CGC) announced Wednesday that it is divesting its subsidiary business, C³ Cannabinoid Compound Company GmbH, to Dermapharm Holding SE, a European pharmac

Canopy Growth Corp. CGC, -1.72% WEED, -1.67% said Wednesday it agreed to sell its Cannabinoid Compound Company GmbH (C3) to Dermapharm Holding SE for up to 122.6 million euros ($138 million). Canopy G

Former Canopy Growth chairman John Bell to take over from Michael Munzar

HEXO Reports First Quarter 2022 Results and Launches New Strategic Plan, “The Path Forward” to Solidify its Position as Canada’s Leading Cannabis Company HEXO Corp (TSX: HEXO; NASDAQ: HEXO) (“HEXO” or the “Company”), a leading producer of high-quality cannabis products, today reported its financial results for the fiscal quarter ended October 31, 2021 (Q1’22), and announced “The Path Forward”, a new strategic plan to solidify itself as Canada’s leading cannabis company and position it to capitalize on international opportunities. The plan utilizes HEXO’s current assets, including its recent acquisitions and unique capabilities to drive accelerated growth and become cash flow positive within the next four quarters. This plan is underpinned by actions to strengthen its balance sheet, its executive team and its corporate governance. Q1 2022 Highlights Total net revenue increased 29% to $50.2 million from $38.7 million in Q4’21, and up 70% from the comparative quarter of fiscal 2021. The Company closed its acquisitions of Redecan and 48North which contributed net revenues of $13.5 Million and $1.1 Million respectively during the two months ended October 31, 2022.

Top Pot Stocks For Your 2022 Watchlist The post Top Canadian Marijuana Stocks To Buy? 2 To Watch Right Now In December appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Bu

The trading price of Canopy Growth Corporation (NASDAQ:CGC) closed lower on Friday, December 10, closing at $9.56, -6.27% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Related Stocks: CGC , VEU , BABA , RWVG , EWU , VIAC ,

Edifying episode with industry expert Brady Cobb. Recent cannabis legislation; moving from optics to real reform. SAFE Banking, uplisting and what it all means for cannabis investors

Canopy Growth (TSE:WEED)s stock had its underweight rating restated by equities researchers at Wells Fargo & Company in a research note issued to investors on Tuesday, Analyst Ratings Network reports. Other equities research analysts also recently issued research reports about the company. CIBC downgraded Canopy Growth from a neutral rating to a sell rating and []

This week, Wells Fargo analyst Chris Carey initiated coverage of four cannabis stocks, helping to rekindle interest in the space on Wall Street ahead of a possible year-end run. The research analyst targeted a handful of stocks including Scotts Miracle-Gro Co (NYSE:SMG) and Canopy Growth Corp. (Nasdaq:CGC) in his analysis. This comes as federal lawmakers [] The post Cannabis Stocks Find Fresh Life What to Do About It (OGI, SGMD, SNDL, TLRY, CGC, ACB, CRON, SMG) appeared first on Wall Street PR .